ArticleActa pharmaceutica Sinica. B2020
A homogenous nanoporous pulmonary drug delivery system based on metal-organic frameworks with fine aerosolization performance and good compatibility.
Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 65 citations in OpenAlex.
- Nanoporous-based biomaterials in biomedical applications: from fundamentals and biosensing to drug delivery, wound healing, and tissue engineering.Nanoscale advances · 2026Review
- γ-Cyclodextrin Metal-Organic Frameworks for Drug Delivery: Current Advances in Synthesis, Activation, Encapsulation and Applications.Pharmaceutics · 2026Review
- Metal-organic frameworks in pharmaceutical research.Pharmaceutical science advances · 2025Review
- Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases.Pharmaceutics · 2025Review
- Cyclodextrin-Based Nanotransporters as a Versatile Tool to Manage Oxidative Stress-Induced Lung Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Preparation of Ibuprofen-Loaded Inhalable γCD-MOFs by Freeze-Drying Using the QbD Approach.Pharmaceutics · 2024Article
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- Metal-organic frameworks: Drug delivery applications and future prospects.ADMET & DMPK · 2024Review
- Synthesis and potential applications of cyclodextrin-based metal-organic frameworks: a review.Environmental chemistry letters · 2023Review
- Inhalable Mannosylated Rifampicin-Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy.Pharmaceutics · 2022Article
- Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.Current drug metabolism · 2022Article
- Self-Stabilized Supramolecular Assemblies Constructed from PEGylated Dendritic Peptide Conjugate for Augmenting Tumor Retention and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design.Acta pharmaceutica Sinica. B · 2021Review
- Vancomycin-Loaded Polycaprolactone Electrospinning Nanofibers Modulate the Airway Interfaces to Restrain Tracheal Stenosis.Frontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary drug delivery has attracted increasing attention in biomedicine, and porous particles can effectively enhance the aerosolization performance and bioavailability of drugs. However, the existing methods for preparing porous particles using porogens have several drawbacks, such as the inhomogeneous and uncontrollable pores, drug leakage, and high risk of fragmentation. In this study, a series of cyclodextrin-based metal-organic framework (CD-MOF) particles containing homogenous nanopores were delicately engineered without porogens. Compared with commercial inhalation carrier, CD-MOF showed excellent aerosolization performance because of the homogenous nanoporous structure. The great biocompatibility of CD-MOF in pulmonary delivery was also confirmed by a series of experiments, including cytotoxicity assay, hemolysis ratio test, lung function evaluation,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.